Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has a strategic partnership with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China. The company was founded in 2004 and is headquartered in Melbourne, Australia.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:MEOBF
Previous Symbol
CUSIPN/A
Phone61 3 9639 6036
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees81
Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable
Mesoblast (OTCMKTS:MEOBF) Frequently Asked Questions
What is Mesoblast's stock symbol?
Mesoblast trades on the OTCMKTS under the ticker symbol "MEOBF."
Has Mesoblast been receiving favorable news coverage?
News headlines about MEOBF stock have trended neutral on Tuesday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Mesoblast earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near future.
Who are some of Mesoblast's key competitors?
Some companies that are related to Mesoblast include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE), Ampliphi Biosciences (APHB) and Antibe Therapeutics (ATE).
Who are Mesoblast's key executives?
Mesoblast's management team includes the folowing people:
- Dr. Silviu Itescu, Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director (Age 61)
- Dr. Donna L. Skerrett, Chief Medical Officer (Age 61)
- Mr. Roger D. Brown BA, Head of Spinal Orthopedic Disorders
- Mr. Michael Schuster MS, BSc, MBA, Head of Pharma Partnering (Age 41)
- Dr. Kenneth M. Borow M.D., Exec. (Age 70)
How do I buy shares of Mesoblast?
Shares of MEOBF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mesoblast's stock price today?
One share of MEOBF stock can currently be purchased for approximately $1.48.
What is Mesoblast's official website?
How can I contact Mesoblast?
The company can be reached via phone at 61 3 9639 6036.
MarketBeat Community Rating for Mesoblast (OTCMKTS MEOBF)
MarketBeat's community ratings are surveys of what our community members think about Mesoblast and other stocks. Vote "Outperform" if you believe MEOBF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEOBF will underperform the S&P 500 over the long term. You may vote once every thirty days.
